TD Cowen analyst Phil Nadeau maintains $Biogen (BIIB.US)$ with a buy rating, and maintains the target price at $275.
According to TipRanks data, the analyst has a success rate of 46.9% and a total average return of 6.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Biogen (BIIB.US)$'s main analysts recently are as follows:
Biogen's approach to counter the decline of its core franchise involves focusing on developing treatments for conditions with a high unmet medical need, despite the challenging nature of these indications. The company's pipeline is perceived to carry a higher clinical risk compared to its major biotech counterparts, which simultaneously offers considerable potential value.
The firm indicated that Biogen's collaborator's successful appeal to the EMA's CHMP for another look at the MAA for a treatment in amyloid-positive early Alzheimer's disease resulted in a favorable recommendation, albeit with an exclusion for a certain genotype. This adjustment is believed to make the proposal more agreeable to the European Commission, with an anticipated approval decision due within 67 days.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
TD Cowen分析师Phil Nadeau维持$渤健公司 (BIIB.US)$买入评级，维持目标价275美元。
根据TipRanks数据显示，该分析师近一年总胜率为46.9%，总平均回报率为6.5%。
此外，综合报道，$渤健公司 (BIIB.US)$近期主要分析师观点如下：
渤健公司应对其核心业务衰退的方法是专注于开发对高度未满足的医疗需求的疾病的治疗，尽管这些适应症的性质具有挑战性。与主要生物技术同行相比，该公司的产品管线被认为承受更高的临床风险，但同时也提供了可观的潜在价值。
该公司表示，渤健公司的合作伙伴成功向欧洲药品管理局的药品评审委员会申请重新审视阿尔茨海默早期淀粉样蛋白阳性治疗方案的市场授权申请，得到了有利的推荐，尽管对某一基因型存在排除。这一调整被认为使该提案更易于获得欧洲委员会的认可，预计将在67天内作出审批决定。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
